- Meeting abstract
- Open Access
Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin
© Lewiński et al; licensee BioMed Central Ltd. 2013
- Published: 5 April 2013
- Serum Concentration
- Matrix Metalloproteinase
- Risk Cardiovascular Disease
- Radioactive Iodine
In order to assess long-term safety of radioactive iodine administration in treatment of thyrotoxicosis, we assessed concentrations of selected markers of risk cardiovascular disease, i.e. matrix metalloproteinase 2 (MMP-2), its main inhibitor TIMP-2, matrix metalloproteinase 9 (MMP-9), its main inhibitor TIMP-1, as well concentrations of anti-inflammatory adiponectin and pro-inflammatory thrombospondin.
The study involved 23 patients (3 males) age 53±12 (mean±SD) years treated with radioiodine for thyrotoxicosis. Serum concentrations TSH, fT4, fT3, MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and thrombospondin were measured just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), six to eight months (visit 4) and 15-18 months after radioiodine administration (visit 5).
There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 adiponectin and thrombospondin (visit 1 versus visit 2). Subsequently, however, there was no change in serum MMP-9 or thrombospondin, but an increase in MMP-2 (from 393±106 ng/ml, to 774 ± 424 ng/ml), TIMP-1 (from 177 ± 76 ng/ml to 296 ± 118 ng/ml), TIMP-2 (from 136±44 ng/ml to 168±41 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to visit 5 respectively, p<0.01). Further analysis, however, revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p<0.05), suggestive of possible decrease in concentrations of free MMP-9.
Our data reveal a significant and sustained increase in serum adiponectin as well as possible decrease of concentration of free MMP-9 after radioiodine administration. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of cardiovascular disease.
The study was financed from the grant of the Polish Ministry of Science and Higher Education, number NN402 476637 (Medical University of Lodz internal grant number: 507-11-384).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.